As a new-type foreign trade service provider driven by technological transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory materials of multiple well-known brands for NMN Beta.
As a research-driven foreign trade enterprise, HiSiaddi is not limited to self-promotion of a single manufacturer’s brand. We objectively analyze multiple high-market-share well-known domestic and global brands and share their major technological advancements and breakthroughs, enabling buyers to access authentic, up-to-date and valuable market intelligence.
If you require more comprehensive and valuable NMN Beta market information, please contact HiSiaddi customer service.
Core breakthrough highlights: The five leading domestic manufacturers have completed third-generation directed evolution modification of key synthetic enzymes (NAMPT, NRK), eliminating highly corrosive raw materials (phosphorus oxychloride) used in traditional chemical phosphorylation. The ratio of active β-NMN configurational isomers has risen from 98.2% to nearly 100%, completely removing inactive α-isomer impurities. Comprehensive raw material production costs have fallen by 27%–33%, with energy consumption per ton of finished product reduced by 22%. Novin Bio complements this with CMR microbial genome knockout technology to lock stable finished product purity at 99.9%, with single heavy metal residues ≤0.0004mg/kg, meeting impurity standards for EU EFSA novel food ingredient access.
Benefits for downstream buyers:
1. 30% higher raw material inventory volume with the same procurement budget, lifting terminal finished product pricing flexibility by 15%–20%.
2. Elimination of secondary refining procedures at downstream formulation factories, cutting incoming inspection cycle time by 50%.
3. Direct regulatory compliance for European, American, Japanese and South Korean health supplement market access, reducing customs detention risks due to compliance failures.
Core breakthrough highlights: Bontac Bio has realized global ton-scale mass production of NMNH (reduced NMN), overcoming the industry-wide pain point of rapid room-temperature oxidative degradation of reduced NMN via patented molecular crystal reconstruction technology. The ambient shelf life of NMNH is extended from 6 months to 36 months, with oral NAD+ conversion efficiency 9–10 times higher than standard β-NMN. The five domestic top manufacturers have simultaneously launched integrated NMN→NMNH co-production lines to expand supply of reduced-form raw materials.
Benefits for downstream buyers: Development of high-absorption premium dietary supplement new products with differentiated positioning against high-priced overseas reduced-form alternatives; end-product premium pricing potential exceeds 40% relative to standard NMN formulations to capture high-end anti-aging niche markets.
Core breakthrough highlights: Aubenyuan and Kingdomway launched modified coated NMN raw materials with pre-fabricated enteric micro-coatings on particle surfaces. Active ingredient retention reaches 97.8% under gastric acid conditions with targeted release in the small intestine; native raw material bioavailability rises from the industry average of 22% to above 89%, eliminating the need for downstream manufacturers to add piperine or additional coating excipients for compounding.
Benefits for downstream buyers: Eliminate excipient procurement and formulation coating processing steps, compressing tablet/capsule production man-hours by 30%; directly market high-absorption claims for end products to lift consumer repurchase rates by over 25%.
Core breakthrough highlights: The five leading manufacturers optimized internal control indicators for injectable-grade NMN with bacterial endotoxin ≤0.2EU/mg, meeting raw material access standards for medical aesthetic serums and medical dressings. Adjusted small-molecule particle size specifications deliver low-irritation NMN variants exclusively for pet nutrition, breaking the historical limitation of NMN applications restricted to human health supplements only.
Benefits for downstream buyers: Source human health supplement, medical aesthetic and pet nutrition raw materials from a single supplier to streamline supply chains and expand end-product revenue channels through new product categories.
Core breakthrough highlights: LAIFE leverages its RevOrganAI intelligent formulation platform, iterating four generations of compound formulas based on a database of over 12 million aging biology datasets to achieve targeted mitochondrial enrichment of NMN in the heart, brain and liver. Human clinical trials recorded a 163% increase in mitochondrial count, with organ NAD+ enrichment 192% higher than traditional formulations at equal dosage. Revigorator’s G5 fifth-generation formulations optimized senolytic cell clearance compound systems, extending sustained NAD+ retention duration from 8 hours to 22 hours.
Benefits for downstream OEM/ODM buyers of overseas brands: Direct development of differentiated targeted niche products (liver-protection, brain anti-aging variants) to avoid homogenized price competition for generic NMN goods.
Core breakthrough highlights: GRANVER independently developed patented UTHPEAK™ crystal form technology for NMNH, enabling blood absorption within 15 minutes post oral administration with steady 24-hour sustained release and in vitro measured absorption rate of 98%. Active potency loss is less than 0.1% after 36 months of ambient storage, resolving high cold-chain warehousing costs for reduced-form raw materials. Full FDA GRAS toxicology filings (LD50＞5000mg/kg) have been completed. MIRAI LAB simultaneously introduced this crystal conversion technology, eliminating full cold-chain logistics requirements for its finished products.
Benefits for downstream buyers: Terminal distributor warehousing costs drop by 60% with no cold storage inventory requirements; long-distance cross-regional logistics losses are drastically reduced, cutting unsold product scrap rates from 12% to below 2%.
Core breakthrough highlights: CELFULL optimized composite NADH preparation technology to synthesize stabilized NADH in situ using β-NMN as a precursor, bypassing metabolic conversion losses within the human body. Blood NAD+ peak concentrations rise by 310% post-administration, breaking the limitation of multi-step in-vivo conversion for traditional NMN. The product has obtained Canadian NPN health food certification.
Benefits for downstream buyers: Launch high-potency NADH finished product lines positioned above standard NMN with end-product retail price premiums of 50%–80% to boost single-item gross profit margins.
Core breakthrough highlights: All five leading overseas brands completed double-blind human clinical trials enrolling 3,000–5,000 participants, quantitatively unifying three core efficacy metrics (sleep improvement, metabolism enhancement, skin anti-aging). Clinical datasets have been published in Nature Aging, enabling standardized labeling of clinically verified efficacy values for finished products and overcoming past advertising compliance limitations of NMN lacking authoritative clinical endorsements.
Benefits for downstream buyers: Legally incorporate clinical trial data as marketing materials for end products to avoid European and American advertising compliance penalties, raise consumer trust and lower channel retail distribution barriers.
1. General end consumers: Comprehensive upgrades in product purity, absorption rate and safety; active ingredient utilization rises 3–7 times at equivalent price points with convenient ambient storage; segmented variants (liver protection, medical aesthetics, pet nutrition) fulfill demand across all age groups.
2. Overseas brand owners & formulation manufacturers: One-stop sourcing of multi-specification, multi-category raw materials from Chinese upstream suppliers; process upgrades cut manufacturing costs, shorten new product iteration cycles by 40% and accelerate differentiated new product launches to capture niche markets.
3. Cross-border distributors & supermarket retail channels: Synchronized reductions in logistics, compliance and product loss costs; full product lines comply with mainstream national food regulations globally, enabling rapid distribution expansion to Southeast Asia, Australia, New Zealand and the EU.
If you require more comprehensive and valuable NMN Beta market information, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
